Karyopharm Therapeutics Announces Eight Presentations on Selective Inhibitors of Nuclear Export (SINE) for Hematologic Malignancies at the American Society of Hematology (ASH) Meeting

NATICK, Mass., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc., a leader in the new field of nuclear transport modulators, announces eight presentations by collaborators covering its SINE CRM1 antagonists at the ASH meeting on December 8-11, 2012, in Atlanta, Georgia. The presentations are being made by different academic collaborators and Karyopharm scientists studying the use of Karyopharm's novel SINEs, including clinical candidate KPT-330 in Phase 1, for the treatment of hematologic malignancies including chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), acute myelogenous leukemia (AML), and blast-crisis chronic myelogenous leukemia (bc-CML).

Five oral presentations will be made:

Dr. Kensuke Kojima of the laboratory of Dr. Michael Andreeff at the MD Anderson Cancer Center (MDACC, Houston) will present "Prognostic Impact and Targeting of CRM1 in Acute Myeloid Leukemia" in Session 604 on Tuesday, December 11, 2012: 8:45 AM, in B211-B212, Level 2, Building B.

Dr. Yu-Tzu Tai of the laboratory of Dr. Ken Anderson, Dana Farber Cancer Institute (DFCI, Boston), will present "CRM1 blockade by novel inhibitors of nuclear export (KPT-SINEs) inhibits multiple myeloma cell growth, osteoclastogenesis, and myeloma-induced osteolysis" in Session 652 on Monday, December 10, 2012: 7:15 AM in the Thomas Murphy Ballroom 4, Level 5, Building B.

Jessica Schmidt from Dr. Keith Stewart's laboratory at the Mayo Clinic (Scottsdale, Arizona) will present "Genome wide studies in Multiple Myeloma identify XPO1/CRM-1 as a critical target validated using the selective inhibitor of nuclear export (SINE) KPT-276" in Session 652 on Monday, December 10, 2012: 3:15 PM, in the Thomas Murphy Ballroom 4, Level 5, Building B.

Chris Walker of the laboratory of Dr. Danillo Perrotti of the Ohio State University will present "Anti-Leukemic activity of the CRM1 inhibitor KPT-330 in advanced CML and Ph+ ALL" in Session 631 on Saturday, December 8, 2012: 1:00 PM, in A411-A42, Level 4, Building A.

Dr. Sharon Shacham, Founder, CSO and Head of Research and Development at Karyopharm, will present "Results of a Phase I Dose Escalation Study of the Novel CRM1 Selective Inhibitor of Nuclear Export (SINE) KPT-335 in Dogs with Spontaneous Non-Hodgkin's Lymphomas (NHL)" This multicenter study was lead by Cheryl London, DVM, PhD, from the Ohio State University, and involves treatment of dogs with newly diagnosed or chemotherapy-relapsed NHL. Most of these canine tumors are closely related to human diffuse large B cell lymphoma (DLBCL), and genomic analyses and responses to drugs show they are very similar to the human disease. Dr. London commented, "There have been no new therapies for dogs with lymphoma in the past 15 years, and observations to date suggest that single agent KPT-335 can control disease in a substantial proportion of affected dogs. I look forward to the further development of this compound." This presentation will take place in Session 625 on Sunday, December 9, 2012: 5:30 PM, in B405-B407, Level 4, Building B.

Three poster presentations will be made:

Dr. Rosa Lapalombella, from the laboratory of Dr. John Byrd at the Ohio State University, will present "Significant in vivo efficacy of the SINE KPT-330 in mouse models of CLL" in Session 604 on Sunday, December 9, 2012, 6:00 PM-8:00 PM, in Hall B1-B2, Level 1, Building B.

Dr. Yoko Tabe, from the laboratory of Dr. Michael Andreeff at the MDACC, will present "Molecular mechanisms of antitumor activity of the Selective Inhibitor of Nuclear Export (SINE) CRM1 antagonist KPT-185 in mantle cell lymphoma" in Session: 604 on Sunday, December 9, 2012, 6:00 PM-8:00 PM, in Hall B1-B2, Level 1, Building B.

Dr. Chirag Acharya in the laboratory of Dr. Ken Anderson at the DFCI will present "CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFκB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma" in Session 652 on Saturday, December 8, 2012, from 5:30 PM-7:30 PM, in Hall B1-B2, Level 1, Building B.

Dr. Sharon Shacham commented, "We are very pleased with the progress in understanding the molecular mechanisms of SINE anti-cancer activity from our many collaborators. The translation of our mouse model work into spontaneous lymphoma in dogs is particularly gratifying. We look forward to continuing these joint efforts and to reporting on our ongoing clinical studies in both humans and animals with cancers."

Karyopharm is currently carrying out human phase 1 studies with KPT-330 in patients with cancer, and anticipates initiating a study towards approval for minor use / minor species with KPT-335 in dogs with lymphoma before the end of the year.

About Karyopharm

Karyopharm Therapeutics Inc. was founded by Drs. Sharon Shacham and Michael Kauffman in 2009 and has emerged as a leader in the new field of nuclear transport modulators. The company's selective inhibitors of nuclear export (SINE) function by trapping multiple tumor suppressor proteins in the nucleus, resulting in anti-cancer activity across multiple tumor types. In collaboration with many academic laboratories, SINEs, targeting the major nuclear exporter CRM1, exert robust anti-cancer activity in diverse preclinical models of cancer. The lead SINE KPT-330 is now in Phase 1 clinical studies for advanced solid tumor and hematologic malignancies. The related SINE KPT-335 is being evaluated as an oral treatment for dogs with Non-Hodgkin's Lymphoma, one of the most common canine cancers. The Company is also testing SINEs in autoimmune, viral and dermatologic disorders. Karyopharm Therapeutics is located in Natick, Massachusetts.

CONTACT: Dr. Michael Kauffman mkauffman@karyopharm.comSource: Karyopharm Therapeutics